Videos
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.
The panel compares cfDNA with ctDNA for assessing MRD, and outlines when ctDNA testing is ordered and how it’s collected.
Joleen Hubbard, MD, compares CEA with ctDNA for monitoring patients with colorectal cancer.
Key opinion leaders in myelofibrosis management reflect on the role of biomarkers in informing treatment selection, even for patients with triple-negative disease.
The expert panel discusses CAR T-cell therapy options and treatment considerations for patients with multiple myeloma.
Al-Ola Abdallah, MD, presents the case of a patient with multiple myeloma treated with CAR T-cell therapy and teclistamab.
Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.
Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.
Key opinion leaders Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, reflect on the use of tocilizumab in patients experiencing cytokine release syndrome on MajesTEC-1.
Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
Subject-matter experts share their perspectives on treatment selection for patients with NDMM.
A summary of updates from the GRIFFIN trial evaluating D-RVd in clinically relevant NDMM patient subgroups.
Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.
The expert panel review recently reported data from clinical trials evaluating menin inhibitors, including ziftomenib and revumenib, in the treatment of relapsed AML and how these treatments may fit into first-line settings.
Daniel Pollyea, MD, MS, discusses first-line treatment options for patients with AML with KMT2a rearrangements.
Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.
Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.
Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.
Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.
Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
Advertisement
Advertisement
